Pre-eclampsia is a complication of pregnancy that has a relatively high frequency. Most women affected by this disorder do not have severe symptoms, but those who develop eclampsia may be affected, both the pregnant woman and the fetus. The consequences in severe cases may range from placental abruption, premature labour, organic failure, seizures, etc. However, if detected in the first trimester of pregnancy, allows appropriate monitoring of the pregnant and the fetus. Preeclampsia may develop in the early stages of pregnancy (early preeclampsia), making it necessary to induce labour before the 34th week of gestation or late pregnancy (late preeclampsia). Current screening for preeclampsia includes ultrasound parameters and early detection of its symptoms (from the 25th week or 34th, more frequent).

Pre-eclampsia test allows the detection of the level of PlGF in maternal blood. Placental Growth Factor (PLGF) is an angiogenic protein produced by the placenta whose synthesis is decreased in women at high risk of preeclampsia.

It is indicated for all pregnant women between 11 and 13 + 6 weeks of gestation, especially those with any of the following risk factors:
• First pregnancy or first pregnancy with new partner;
• Previous pregnancy with pre-eclampsia or if her mother had pre-eclampsia;
• Diabetes type I;
• Body mass index greater than 35;
• It is over 40 years old;
• Multiple pregnancy;
• High blood pressure, kidney problems and / or diabetes;
• In vitro fertilization.

Chemiluminescence